266Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
نویسندگان
چکیده
266. Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies Sailaja Puttagunta, MD; Helen Boucher, MD, FIDSA; George Talbot, MD; Mark Wilcox, MD; Michael Dunne, MD; Durata Therapeutics, Branford, CT; Tufts New England Medical Center, Boston, MA; Talbot Advisors LLC, Anna Maria, FL; Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom
منابع مشابه
Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials
BACKGROUND The objective of this analysis was to evaluate the efficacy and safety of oritavancin compared with vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSIs) who received treatment in the outpatient setting in the Phase 3 SOLO clinical trials. METHODS SOLO I and SOLO II were 2 identically designed comparative, multicenter, double-blind, randomized st...
متن کامل675Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
(ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program Sailaja Puttagunta, MD; Mark Wilcox, MD; Helen Boucher, MD, FIDSA; George Talbot, MD; Michael Dunne, MD; Durata Therapeutics, Branford, CT; Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom; Tufts New England Medical Center, Boston, MA; Talbot Advisors LLC...
متن کامل1331The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
1331. The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Ralph Corey, MD; Matthew Wikler, MD; Greg Moeck,; Hai Jiang,; Samantha Good,; Solo I and II Investigators; Medicine Infectious Diseases, Duke University Medical Center, Durham, NC; The Medicines Company, Parsippany, NJ
متن کاملSystematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA
BACKGROUND Tedizolid, the active moiety of tedizolid phosphate, is approved in the United States, the European Union, Canada and a number of other countries for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This network meta-analysis (NMA) evaluates the comparativ...
متن کاملAntimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.
BC-3781 is a novel semisynthetic pleuromutilin antimicrobial agent developed as an intravenous and oral therapy for acute bacterial skin and skin structure infections (ABSSSI) and respiratory tract infections (RTI). BC-3781 and comparator agents were tested by the broth microdilution method against 1,893 clinical Gram-positive organisms predominantly causing ABSSSI. BC-3781 exhibited potent act...
متن کامل